NeuroPace falls as Delta variant, shortage of nurses hurt sales

NeuroPace

11/11/2021 16:11

** Medical device maker's shares  NPCE.O  fall 14.8% to
$13.46 - their lowest since April debut 
    ** Shares set for their fourth straight session of losses 
    ** Co says sales of its brain implants to treat epilepsy
patients fell 15% in Q3 to $9.2 mln, due to hospitals delaying
non-urgent surgery because of the Delta variant and staffing
limitations  urn:newsml:reuters.com:*:nGNX4Fd573
    ** Cuts FY sales view to $44 to $44.5 million, from prior
forecast of $47 mln 
    ** Including session losses, stock has fallen ~46% since its
IPO 

 (Reporting by Manas Mishra)
 ((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manasmishra24))